Log in
RegisterRelativ potency (Finney) [Power / Sample Size]
Dear all,
imagine a 4-sequence, 4-period, 4 treatment crossover study as described in the Canadian guideline „Guidance to establish equivalence or relative potency of safety and efficacy of a second entry short-acting beta 2- agonist metered dose inhaler“. According Richard C. Ahrens et. al. for example “Asthma Stability after Oral prednisone” sample size depends on the ratio of slope and variability.
Does anybody knows how to calculate sample size for relative potency, in crossover or parallel group studies ?
Best regards,
earlybird
--
Edit: Category and subject line changed. [Jaime]
imagine a 4-sequence, 4-period, 4 treatment crossover study as described in the Canadian guideline „Guidance to establish equivalence or relative potency of safety and efficacy of a second entry short-acting beta 2- agonist metered dose inhaler“. According Richard C. Ahrens et. al. for example “Asthma Stability after Oral prednisone” sample size depends on the ratio of slope and variability.
Does anybody knows how to calculate sample size for relative potency, in crossover or parallel group studies ?
Best regards,
earlybird
--
Edit: Category and subject line changed. [Jaime]
Complete thread:
- Relativ potency (Finney)earlybird 2009-12-07 09:14
![[Mix]](https://static.bebac.at/img/mix.png "open in Mix view")
- Relativ potency (Finney) Helmut 2009-12-07 15:07
Ing. Helmut Schütz